iShares Nasdaq Biotechnology (IBB)-NasdaqGM Typically, the best indicator of the action in our biotech portfolio is the $IBB. By looking at it we get the whole picture of the pressure that we as investors or traders in the biotech sector have felt in the past 4 trading weeks after the euphoria and the hype that […]
ACAD – The Last Run to The Parkinson’s Disease Psychosis Results
ACADIA Pharmaceuticals Inc. (ACAD) -NasdaqGM Catalyst: late Nov. P-III results for Parkinson disease Acadia reported a 100% patient enrollment on Sep 05th: ACADIA Pharmaceuticals Announces Completion of Enrollment in Phase III Pimavanserin Trial in Parkinson’s Disease Psychosis Top-Line Data Expected in November 2012, as I mentioned earlier in my last report and since 09/07 the […]
CPRX – Volatility Squeeze Ahead of The Tope-Line Results
Catalyst Pharmaceutical Partners Inc. (CPRX) -NasdaqCM Catalyst: Phase IIb trial results Sentiment : Bullish This report is supplement to the thorough report by Jason Chew, release earlier this week. In that report, he outlined the history of CPRX & it’s upcoming catalyst: Tiny Catalyst Pharmaceutical Partners (CPRX) is expected to disclose top-line results from its […]
EXEL – Looking for Direction Ahead of the PDUFA date
Exelixis (NASDAQ: EXEL) On 5/30/12, Exelixis submitted their NDA for Cabozantinib as a treatment for patients with progressive, unresectable, locally advanced, or metastatic medullary thyroid cancer (MTC). They were subsequently granted priority review with a PDUFA date set for 11/29/12. Recently, the FDA announced they had planned to hold an Advisory Committee to discuss this […]
BMRN – A Busy Quarter Ahead.
BioMarin (NASDAQ:BMRN) $BMRN is a ticker that every biotech investor or trader would like to see it in his portfolio. Just look at the weekly chart to understand the huge & steady uptrend, $BMRN had a huge run since Mar 2009 starting at $10 and running to $41 these days, it’s more than 400% in […]
INCY – Is It A Good Time To Start A Position?
Incyte Corporation (INCY) The chart of INCY pop up in my chart screener, as a chart with a bullish reversal pattern called “Tripple Bottom” . The Triple Bottom Reversal is a bullish reversal pattern, Once the first bottom is created, the price reaches a peak and retraces back toward the prior support. This is when […]
ZIOP – Trading In an Uptrend Channel
Ziopharm(NASDAQ: ZIOP) In Patrick’s latest article “Smallcap Phase 3 data expected by year-end 2012” he mentions Ziopharm’s current Phase 3 trial of Palifosfamide. This Phase 3 trial, known as PICASSO 3, is testing Palifosfamide (Zymafos or ZIO-201) in addition to Doxorubicin versus Doxorubicin in front-line metastatic soft tissue sarcoma. The trial completed enrollment on June 2nd. […]
EXEL – In A Consolidation Mode
EXEL “Exelixis” had an impressive uptrend starting in June 2012, anticipating the FDA reply for the NDA filling & priority review, starting from the $4.40 area, reaching the $6.95 point on the day of the announcement that the FDA accepted its potential medullary thyroid cancer (MTC) treatment, cabozantinib, for priority review , which is shorter […]
